# Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

> **NCT06833268** · — · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 228 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **OTHER:** No drug

## Key facts

- **NCT ID:** NCT06833268
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-20
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06833268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06833268, "Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06833268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*